Day Gain | ||
Gain | ||
Market Val | ||
Costs | ||
Cash | ||
Portfolio | ||
Realized | ||
Dividend |
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-11-07 | 2024-09 | 4.53 | N/A | N/A | N/A |
2024-08-08 | 2024-06 | 2.64 | 3.92 | 1.28 | 48.48% |
2024-04-30 | 2024-03 | 2.53 | 2.58 | 0.05 | 1.98% |
2024-02-06 | 2023-12 | 2.47 | 2.49 | 0.02 | 0.81% |
2023-11-02 | 2023-09 | -0.08 | 0.1 | 0.18 | 225.00% |
2023-08-08 | 2023-06 | 1.98 | 2.11 | 0.13 | 6.57% |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-10-10 | Morgan Stanley | Upgrade | Overweight | Overweight |
2023-10-08 | Wells Fargo | Upgrade | Overweight | Overweight |
2023-10-08 | Cantor Fitzgerald | Upgrade | Overweight | Overweight |
2023-10-01 | Cantor Fitzgerald | Upgrade | Overweight | Overweight |
2023-09-04 | Cantor Fitzgerald | Upgrade | Overweight | Overweight |
2023-09-04 | Morgan Stanley | Upgrade | Overweight | Overweight |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2024-09-15 | ALVAREZ RALPH | Director | 54.25K | Stock Award(Grant) |
2024-08-11 | HAKIM ANAT | General Counsel | 30.48K | Stock Gift |
2024-09-15 | HEDLEY MARY LYNNE | Director | 1.64K | Stock Award(Grant) |
2024-09-15 | JOHNSON KIMBERLY H | Director | 2.69K | Stock Award(Grant) |
2024-09-02 | LILLY ENDOWMENT, INC. | Beneficial Owner of more than 10% of a Class of Security | 96.89M | Sale |
2024-09-15 | LUCIANO JUAN R | Director | 15.81K | Stock Award(Grant) |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-09-29 | Lilly Endowment, Inc | 99.98M | 53.70B | 10.53% |
2023-06-29 | Vanguard Group Inc | 69.92M | 32.79B | 7.37% |
2023-06-29 | Blackrock Inc. | 64.45M | 30.23B | 6.79% |
2023-06-29 | PNC Financial Services Group, Inc. | 51.87M | 24.33B | 5.46% |
2023-06-29 | State Street Corporation | 33.88M | 15.89B | 3.57% |
2023-06-29 | FMR, LLC | 32.80M | 15.38B | 3.46% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Total Stock Market Index Fund | 26.65M | 12.50B | 2.81% |
2023-06-29 | Vanguard 500 Index Fund | 18.76M | 8.80B | 1.98% |
2023-06-29 | Vanguard/Primecap Fund | 13.35M | 6.26B | 1.41% |
2023-05-30 | Fidelity 500 Index Fund | 8.83M | 3.79B | 0.93% |
2023-08-30 | SPDR S&P 500 ETF Trust | 8.68M | 4.81B | 0.91% |
2023-08-30 | iShares Core S&P 500 ETF | 7.37M | 4.08B | 0.78% |
Dividend | Date |
---|---|
1.3 | 2024-08-15 |
1.3 | 2024-05-15 |
1.3 | 2024-02-15 |
1.3 | 2024-02-14 |
1.13 | 2023-11-14 |
1.13 | 2023-09-08 |
Split | Date |
---|---|
2 : 1 | 1997-10-16 |
2 : 1 | 1995-12-21 |
2 : 1 | 1989-05-01 |
2 : 1 | 1986-01-30 |
-
$LLY BEST OF BREED PERIOD !!!
-
$LLY On sale here. Oversold on bad info.
Amgen will need 3 years to get to market.
Lilly has best of breed with a pill coming.
They also will own the market in Alzheimer’s, liver, disease, diabetes, and others.
$1,500 this year. -
$LLY Amgen won’t make a cent for years.
Incredibly Undervalued Here. $1,500 eoy -
$LLY Best Of Breed Period. Weight Loss, Alzheimer’s, Liver Disease, Diabetes. These are
all Multi Billion Drugs close to approval.
$2,500 in 2 years. -
$LLY Amgen is years away with no approvals.
People are stupid and overreacting. Sales here are exploding with several other high value drugs ready for approval and people are selling???
I am buying these dips. See you at $1,200+ eoy -
$LLY Laughably Undervalued Here.
BEST OF BREED PERIOD -
$LLY Screaming Buy. Best of Breed Period.
https://www.fool.com/investing/2024/05/02/heres-why-eli-lilly-stock-remains-a-screaming-buy/
-
-
-
-
$LLY open at $785, high of $794 and then drop to $760-$770 range
-
$LLY
SEE YOU AT $1,000 SOON -
$LLY Cut to Dumb BearTards Icing the Butthole
-
“makes no sense”
youre right, it doesnt
-
JPMorgan reiterates Eli Lilly as overweight
JPMorgan said it’s bullish heading into earnings on April 30.
“More broadly on the story, LLY remains one of our favorite names in the group as we see further upside to Street estimates as Mounjaro continues to ramp and Zepbound fully launches as well as a number of additional incretin datapoints
-
Opportunity knocking
-
$LLY My Nephew works here and I ask all the time for details and he only says “buy all you can uncle
-
ResMed stock cut at Wolfe on Lilly GLP-1 threat (NYSE:RMD)
news.google.com • -
December 20th Options Now Available For Eli Lilly (LLY)
news.google.com • -
Eli Lilly (LLY) Stock Price Prediction and Forecast 2025-2030
news.google.com • -
Eli Lilly Stock Up 21% in 6 Months: Time to Add to Your Portfolio?
news.google.com • -
Looking Into Eli Lilly's Recent Short Interest
news.google.com • -
Eli Lilly Stock Up 21% in 6 Months: Time to Add to Your Portfolio?
news.google.com • -
Eli Lilly Stock Up 21% in 6 Months: Time to Add to Your Portfolio?
news.google.com • -
Is Most-Watched Stock Eli Lilly and Company (LLY) Worth Betting on Now?
news.google.com • -
Eli Lilly (LLY) Stock Price Prediction and Forecast 2025-2030
news.google.com • -
Lilly Gets FDA Approval for Eczema Drug Ebglyss
zacks.com • -
Morgan Stanley’s Best Stock Picks: 15 Stocks To Own For 2025
news.google.com • -
(LLY) Long Term Investment Analysis
news.google.com • -
Do queasy side effects mean the end of weight-loss drug stock hype?
news.google.com • -
Is Eli Lilly and Company (LLY) an Unstoppable Dividend Stocks to Buy?
news.google.com • -
Eli Lilly and Co (LLY) Stock Price, Trades & News
news.google.com • -
Eli Lilly stock gains as Citi resumes at buy (NYSE:LLY)
news.google.com • -
Eli Lilly (LLY) Stock Price Prediction and Forecast 2025-2030
news.google.com • -
NVO Oral Obesity Pill Tops Wegovy; LLY, VKTX, GPCR Stocks Rise
news.google.com • -
Bull of the Day: Eli Lilly (LLY)
news.google.com •